Your front row seat to the future of biopharma
The Institute@Precision was created to bring together the people driving discovery, development, and delivery, and to turn their collective experience into shared insight. This isn't just thought leadership - it's a collaborative space for learning, connecting, and accelerating progress across the entire precision ecosystem.
1Q 2026 Topic: Radiopharmaceuticals
Radiopharmaceuticals Deep Dive
Radiopharmaceuticals present enormous promise for the next generation of oncology treatments. How can we address the clinical, logistical, manufacturing, and other challenges these therapies present?
1Q 2026 Topic: Radiopharmaceuticals
Advancing Radiopharmaceuticals From Regulatory Approval to Global Access
1Q 2026 Topic: Radiopharmaceuticals
Wall Street Perspective on Radiopharmaceuticals
1Q 2026 Topic: Radiopharmaceuticals
Navigating Global Regulations for Radiopharmaceutical Development
1Q 2026 Topic: Radiopharmaceuticals
Challenges and Opportunities for Radiopharmaceutical Commercialization
1Q 2026 Topic: Radiopharmaceuticals
Managing Operational Complexity in Early-Phase Oncology Radiopharmaceutical Trials
Featured content
The ADC Pendulum: Following the Arc from Approval to Withdrawal and Renewed Promise
Moving ADCs to the Front Line: Perspectives from FDA Oncology Experts
Twenty-Five Years of Antibody–Drug Conjugates: From Breakthroughs to Access by Design
The oncology landscape has been fundamentally reshaped over the past 25 years by antibody–drug conjugates (ADCs). By combining the precision targeting of an antibody with a potent cytotoxic payload, ADCs have evolved from early promise to established, high-impact therapies across multiple tumor types.